Skip to content
PIL Logo

Emtricitabine/Tenofovir disoproxil 200 mg/245 mg Film-Coated Tablets

Last Updated on eMC 09-Nov-2017 View changes  | Dr. Reddy's Laboratories (UK) Ltd Contact details

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Please click on the link to the left to view the PIL in PDF format.

Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link to the left. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000.



Emtricitabine/Tenofovir disoproxil 200 mg/245 mg Film-Coated Tablets

Package leaflet: Information for the user

Emtricitabine/Tenofovir disoproxil 200 mg/245 mg Film-Coated Tablets

Emtricitabine/tenofovir disoproxil

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Emtricitabine/Tenofovir disoproxil is and what it is used for
2. What you need to know before you take Emtricitabine/Tenofovir disoproxil
3. How to take Emtricitabine/Tenofovir disoproxil
4. Possible side effects
5. How to store Emtricitabine/Tenofovir disoproxil
6. Contents of the pack and other information

1. What Emtricitabine/Tenofovir disoproxil is and what it is used for

Emtricitabine/Tenofovir disoproxil tablets contain two active substances,emtricitabine and tenofovir disoproxil succinate. Both of these active substances are antiretroviral medicines which are used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor and tenofovir is a nucleotide reverse transcriptase inhibitor. However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself.

Emtricitabine/Tenofovir disoproxil is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection, in adults aged 18 years and over.

  • Emtricitabine/Tenofovir disoproxil should always be used combined with other medicines to treat HIV infection.
  • Emtricitabine/Tenofovir disoproxil can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.

People who are HIV positive can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other people.

This medicine is not a cure for HIV infection. While taking Emtricitabine/Tenofovir disoproxil you may still develop infections or other illnesses associated with HIV infection.

  • Emtricitabine/Tenofovir disoproxil is also used to reduce the risk of getting HIV-1 infection, when used as a daily treatment, together with safer sex practices:

See section 2 for a list of precautions to take against HIV infection.

2. What you need to know before you take Emtricitabine/Tenofovir disoproxil

Do not take Emtricitabine/Tenofovir disoproxil to treat HIV or to reduce the risk of getting HIV if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil succinate, or any of the other ingredients of this medicine (listed in section 6).

  • If this applies to you, tell your doctor immediately.

Before taking Emtricitabine/Tenofovir disoproxil to reduce the risk of getting HIV:

Emtricitabine/Tenofovir disoproxil can only help reduce your risk of getting HIV before you are infected.

  • You must be HIV negative before you start to take Emtricitabine/Tenofovir disoproxil to reduce the risk of getting HIV. You must get tested to make sure that you do not already have HIV infection. Do not take Emtricitabine/Tenofovir disoproxil to reduce your risk unless you are confirmed to be HIV negative. People who do have HIV must take Emtricitabine/Tenofovir disoproxil in combination with other drugs.
  • Many HIV tests can miss a recent infection. If you get a flu-like illness, it could mean you have recently been infected with HIV. These may be signs of HIV infection:
    • tiredness
    • fever
    • joint or muscle aches
    • headache
    • vomiting or diarrhoea
    • rash
    • night sweats
    • enlarged lymph nodes in the neck or groin
  • Tell your doctor about any flu-like illness - either in the month before starting Emtricitabine/Tenofovir disoproxil, or at any time while taking Emtricitabine/Tenofovir disoproxil.

Warnings and precautions

While taking Emtricitabine/Tenofovir disoproxil to reduce the risk of getting HIV:

  • Take Emtricitabine/Tenofovir disoproxil every day to reduce your risk, not just when you think you have been at risk of HIV infection. Do not miss any doses of Emtricitabine/Tenofovir disoproxil, or stop taking it. Missing doses may increase your risk of getting HIV infection.
  • Get tested for HIV regularly.
  • If you think you were infected with HIV, tell your doctor straight away. They may want to do more tests to make sure you are still HIV negative.
  • Just taking Emtricitabine/Tenofovir disoproxil may not stop you getting HIV.
  • Always practice safer sex. Use condoms to reduce contact with semen, vaginal fluids, or blood.
  • Do not share personal items that can have blood or body fluids on them, such as toothbrushes and razor blades.
  • Do not share or re-use needles or other injection or drug equipment.
  • Get tested for other sexually transmitted infections such as syphilis and gonorrhoea. These infections make it easier for HIV to infect you.

Ask your doctor if you have any more questions about how to prevent getting HIV or spreading HIV to other people.

While taking Emtricitabine/Tenofovir disoproxil to treat HIV or to reduce the risk of getting HIV:

  • Emtricitabine/Tenofovir disoproxil may affect your kidneys. Before and during treatment, your doctor may order blood tests to assess kidney function. Tell your doctor if you have had kidney disease, or if tests have shown kidney problems. If you have kidney problems, your doctor may advise you to stop taking Emtricitabine/Tenofovir disoproxil or, if you already have HIV, to take Emtricitabine/Tenofovir disoproxil less frequently. Emtricitabine/Tenofovir disoproxil is not recommended if you have severe kidney disease or are on dialysis.
    Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects).
  • Talk to your doctor if you have a history of liver disease, including hepatitis, Patients infected with HIV who also have liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B or C, your doctor will carefully consider the best treatment regimen for you.
  • Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil. If you have HBV, there is a serious risk of liver problems when you stop taking Emtricitabine/Tenofovir disoproxil, whether or not you also have HIV. It is important not to stop taking Emtricitabine/Tenofovir disoproxil without talking to your doctor: see section 3, Do not stop taking Emtricitabine/Tenofovir disoproxil.
  • Talk to your doctor if you are over 65. Emtricitabine/Tenofovir disoproxil has not been studied in patients over 65 years of age.
  • Talk to your doctor if you are intolerant to lactose (see Emtricitabine/Tenofovir disoproxil tablets contain lactose later in this section).

Children and adolescents

Emtricitabine/Tenofovir disoproxil is not for use in children and adolescents under 18 years of age.

Other medicines and Emtricitabine/Tenofovir disoproxil

Do not take Emtricitabine/Tenofovir disoproxil if you are already taking other medicines that contain the components of Emtricitabine/Tenofovir disoproxil, emtricitabine and tenofovir disoproxil, or any other antiviral medicines that contain tenofovir alafenamide, lamivudine or adefovir dipivoxil.

Taking Emtricitabine/Tenofovir disoproxil with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including

  • aminoglycosides (for bacterial infection)
  • amphotericin B (for fungal infection)
  • foscarnet (for viral infection)
  • ganciclovir (for viral infection)
  • pentamidine (for infections)
  • vancomycin (for bacterial infection)
  • interleukin-2 (to treat cancer)
  • cidofovir (for viral infection)
  • non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)

If you are taking another antiviral medicine called a protease inhibitor to treat HIV, your doctor may order blood tests to closely monitor your kidney function.

It is also important to tell your doctor if you are taking ledipasvir/sofosbuvir to treat hepatitis C infection.

Taking Emtricitabine/Tenofovir disoproxil with-other medicines containing didanosine (for treatment of HIV infection): Taking Emtricitabine/Tenofovir disoproxil with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts. Rarely, inflammation of the pancreas and lactic acidosis ( excess lactic acid in the blood), which sometimes causes death, have been reported when medicines containing tenofovir disoproxil and didanosine were taken together. Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine.

  • Tell your doctor if you are taking any of these medicines. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Emtricitabine/Tenofovir disoproxil with food and drink

Whenever possible Emtricitabine/Tenofovir disoproxil should be taken with food.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

  • Although there are limited clinical data on the use of Emtricitabine/Tenofovir disoproxil in pregnant women, it is not usually used unless absolutely necessary.
  • If you are a woman who could get pregnant during treatment with Emtricitabine/Tenofovir disoproxil, you must use an effective method of contraception to avoid becoming pregnant.
  • If you become pregnant, or plan to become pregnant, ask your doctor about the potential benefits and risks of therapy with Emtricitabine/Tenofovir disoproxil to you and your child.

If you have taken Emtricitabine/Tenofovir disoproxil during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

  • Do not breast-feed during treatment with Emtricitabine/Tenofovir disoproxil. This is because the active substances in this medicine pass into human breast milk.
  • If you are a woman with HIV it is recommended that you do not breast-feed, to avoid passing the virus to the baby in breast milk.

Driving and using machines

Emtricitabine/Tenofovir disoproxil can cause dizziness. If you feel dizzy while taking Emtricitabine/Tenofovir disoproxil, do not drive and do not use any tools or machines.

Emtricitabine/Tenofovir disoproxil tablets contain lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Emtricitabine/Tenofovir disoproxil

  • Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose of Emtricitabine/Tenofovir disoproxil to treat HIV or to reduce the risk of getting HIV is:

  • Adults: one tablet each day. Whenever possible, Emtricitabine/Tenofovir disoproxil should be taken with food.

If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. Then mix the powder with about 100 ml (half a glass) of water, orange juice or grape juice, and drink immediately.

  • Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.
  • If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil with other antiretroviral medicines. Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
  • If you are taking Emtricitabine/Tenofovir disoproxil to reduce the risk of getting HIV, take Emtricitabine/Tenofovir disoproxil every day, not just when you think you have been at risk of HIV infection.

Ask your doctor if you have any questions about how to prevent getting HIV or prevent spreading HIV to other people.

If you take more Emtricitabine/Tenofovir disoproxil than you should

If you accidentally take more than the recommended dose of Emtricitabine/Tenofovir disoproxil, contact your doctor or nearest emergency department for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.

If you forget to take Emtricitabine/Tenofovir disoproxil

It is important not to miss a dose of Emtricitabine/Tenofovir disoproxil.

  • If you notice within 12 hours of the time you usually take Emtricitabine/Tenofovir disoproxil, take the tablet preferably with food as soon as possible. Then take the next dose at your usual time.
  • If you notice 12 hours or more after the time you usually take Emtricitabine/Tenofovir disoproxil, forget about the missed dose. Wait and take the next dose preferably with food, at your usual time.

If you vomit less than 1 hour after taking Emtricitabine/Tenofovir disoproxil, take another tablet. You do not need to take another tablet if you were sick more than 1 hour after taking Emtricitabine/Tenofovir disoproxil.

Do not stop taking Emtricitabine/Tenofovir disoproxil

  • If you take Emtricitabine/Tenofovir disoproxil for treatment of HIV infection, stopping tablets may reduce the effectiveness of the anti-HIV therapy recommended by your doctor.
  • If you are taking Emtricitabine/Tenofovir disoproxil to reduce the risk of getting HIV, do not stop taking Emtricitabine/Tenofovir disoproxil or miss any doses. Stopping use of Emtricitabine/Tenofovir disoproxil, or missing doses, may increase your risk of getting HIV infection.
  • Do not stop taking Emtricitabine/Tenofovir disoproxil without contacting your doctor.
  • If you have hepatitis B, it is especially important not to stop your Emtricitabine/Tenofovir disoproxil treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis which may be life threatening.
  • Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Possible serious side effects:

  • Lactic acidosis (excess lactic acid in the blood) is a rare but potentially life-threatening side effect. Lactic acidosis occurs more often in women, particularly if they are overweight, and in people with liver disease. The following may be signs of lactic acidosis:
    • deep rapid breathing
    • drowsiness
    • feeling sick (nausea), being sick (vomiting)
    • stomach pain
  • If you think you may have lactic acidosis, contact your doctor immediately.
  • Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is thought that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
  • Autoimmune disorders, when the immune system attacks healthy body tissue, may also occur after you start taking medicines to treat HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:
    • muscle weakness
    • weakness beginning in the hands and feet and moving up towards the trunk of the body
    • palpitations, tremor or hyperactivity
  • If you notice these or any symptoms of inflammation or infection, get medical help immediately.

Possible side effects

Very common side effects

(may affect more than 1 in 10 people)

  • diarrhoea, being sick (vomiting), feeling sick (nausea)
  • dizziness, headache
  • rash
  • feeling weak

Tests may also show:

  • decreases in phosphate in the blood
  • increased creatine kinase

Common side effects

(may affect up to 1 in 10 people)

  • pain, stomach pain
  • difficulty sleeping, abnormal dreams
  • problems with digestion resulting in discomfort after meals, feeling bloated, flatulence
  • rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
  • other allergic reactions, such as wheezing, swelling or feeling light-headed

Tests may also show:

  • low white blood cell count (a reduced white blood cell count can make you more prone to infection)
  • increased triglycerides (fatty acids), bile or sugar in the blood
  • liver and pancreas problems

Uncommon side effects

(may affect up to 1 in 100 people)

  • pain in the abdomen (tummy) caused by inflammation of the pancreas
  • swelling of the face, lips, tongue or throat
  • anaemia (low red blood cell count)
  • breakdown of muscle, muscle pain or weakness which may occur due to damage to the kidney tubule cells

Tests may also show:

  • decreases in potassium in the blood
  • increased creatinine in your blood
  • changes to your urine

Rare side effects

(may affect up to 1 in 1,000 people)

  • Lactic acidosis (see Possible serious side effects)
  • fatty liver
  • yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver
  • inflammation of the kidney, passing a lot of urine and feeling thirsty, kidney failure, damage to kidney tubule cells
  • softening of the bones (with bone pain and sometimes resulting in fractures)
  • back pain caused by kidney problems

Damage to kidney tubule cells may be associated with breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood.

  • If you notice any of the side effects listed above or if any of the side effects get serious, talk to your doctor or pharmacist.

The frequency of the following side effects is not known.

  • Bone problems. Some patients taking combination antiretroviral medicines such as Emtricitabine/Tenofovir disoproxil may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are:
    • joint stiffness
    • joint aches and pains (especially of the hip, knee and shoulder)
    • difficulty with movement
  • If you notice any of these symptoms tell your doctor.

During treatment for HIV there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Emtricitabine/Tenofovir disoproxil

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date refers to the last day of that month.

Use within 30 days after first opening; store below 25°C.

Store in the original package in order to protect from moisture. Keep the container tightly closed.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Emtricitabine/Tenofovir disoproxil tablets contain

  • The active substances areemtricitabine and tenofovir.
    Each Emtricitabine/Tenofovir disoproxil film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300.6 mg of tenofovir disoproxil succinate).
  • The other ingredients are lactose monohydrate, microcrystalline cellulose (E 460), starch pregelatinised maize, croscarmellose sodium, magnesium stearate (E 470b), poly(vinyl alcohol) (E 1203), titanium dioxide (E 171), macrogol 4000 (E 1521), talc (E 553b), indigo carmine aluminium lake (E 132).

What Emtricitabine/Tenofovir disoproxil tablets look like and contents of the pack

Emtricitabine/Tenofovir disoproxil 200 mg and 245 mg film-coated tablets are blue coloured, capsule shaped film-coated tablets, plain on both sides. The dimensions of the tablet are 19.3 mm x 8.8 mm.

Emtricitabine/Tenofovir disoproxil 200 mg and 245 mg film-coated tables are supplied in HDPE bottles of 30 tablets. Each bottle contains a silica gel desiccant canister that must be kept in the bottle to help protect your tablets from moisture. The silica gel desiccant is contained in a separate plastic canister and should not be swallowed.

The following pack sizes are available:

30 (1 x 30), 60 (2 x 30) and 90 (3 x 30) film-coated tablets

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Dr. Reddy's Laboratories (UK) Ltd.
6 Riverview Road
Beverley
East Yorkshire
HU17 0LD
United Kingdom

Manufacturer

Remedica Ltd
Aharnon Street
Limassol Industrial Estate
3056 Limassol
Cyprus

This leaflet was last revised in 05/2017

DR277244

Company contact details

Dr. Reddy's Laboratories (UK) Ltd

Company image
Address

6 Riverview Road, Beverley, Hull, HU17 0LD

Fax

+44 (0)1482 860204

Medical Information e-mail
Medical Information Fax

+44 (0)1748 828801

Telephone

+44 (0)1482 860228

Medical Information Direct Line

+44 (0)1748 828873

Customer Care direct line

+44 (0)1482 389858

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

emtricitabine, tenofovir disoproxil succinate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue